Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease

International Journal of Cardiology

Volumn 120, Issue 1, 2007, Pages 79-84

  Marazzi, Giuseppe ^a,b   Wajngarten, Mauricio ^a,b   Vitale, Cristiana ^a,b   Patrizi, Roberto ^a,b   Pelliccia, Francesco ^a,b   Gebara, Otavio ^a,b   Pierri, Humberto ^a,b   Ramires, Josè Antonio F ^a,b   Volterrani, Maurizio ^a,b   Fini, Massimo ^a,b   Rosano, Giuseppe M C ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes mellitus; Myocardial ischema; Prognosis; Therapy

Indexed keywords

FATTY ACID; GLYCOSYLATED HEMOGLOBIN; PLACEBO; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE ANATOMY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETIC PATIENT; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; FATTY ACID METABOLISM; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZATION; STANDARD; STATISTICAL DISTRIBUTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 34347215790     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.08.082     Document Type: Article

References (43)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 9 (Sep 1998) 1414-1431
2. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
3. Miettinen H., Lehto S., Salomaa V., et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21 (1998) 69-75
4. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 4 (Jul 23 1998) 229-234
5. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
6. Kanters S.D., Banga J.D., Stolk R.P., and Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med 4 2 (1999) 67-75
7. Langer A., Freeman M.R., Josse R.G., et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 67 (1991) 1073-1078
8. Zarich S., Waxman S., Freeman R.T., et al. Effect of autonomic nervous system on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 24 (1994) 956-962
9. Stanley W.C., Lopaschuk G.D., and McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34 1 (Apr 1997) 25-33
10. Stanley W.C., Hall J.L., Smith K.R., Cartee G.D., Hacker T.A., and Wisneski J.A. Myocardial glucose transporters and glycolytic metabolism during ischemia in hyperglycemic diabetic swine. Metabolism 43 1 (Jan 1994) 61-69
11. Rodrigues B., Cam M.C., and McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180 1-2 (Mar 1998) 53-57
12. Osorio J.C., Stanley W.C., Linke A., et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106 5 (Jul 30 2002) 606-612
13. Stanley W.C., Lopaschuk G.D., and McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34 1 (Apr 1997) 25-33
14. Hall J.L., Lopaschuk G.D., Barr A., Bringas J., Pizzurro R.D., and Stanley W.C. Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels. Cardiovasc Res 32 5 (Nov 1996) 879-885
15. American Diabetes Association. Clinical practice guidelines (2001)
16. Chiariello M., Indolfi C., Cotecchia M.R., Sifola C., Romano M., and Condorelli M. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J 110 (1985) 529-534
17. MiSAD Study Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulindependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 79 (1997) 134-139
18. Rutter M.K., Wahid S.T., McComb J.M., and Marshall S.M. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 40 (2002) 56-61
19. Langer A., Freeman M.R., Josse R.G., Steiner G., and Armstrong P.W. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 67 (1991) 1073-1078
20. Hume L., Oakley G.D., Boulton A.J., Hardisty C., and Ward J.D. Asymptomatic myocardial ischemia in diabetes and its relationship to diabetic neuropathy: an exercise electrocardiography study in middle-aged diabetic men. Diabetes Care 9 (1986) 384-388
21. Koistinen M.J. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. BMJ 301 (1990) 92-95
22. Valensi P., Sachs R.N., Harfouche B., et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 24 (2001) 339-343
23. Wackers F.J., Young L.H., Inzucchi S.E., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27 (2004) 1954-1961
24. Inoguchi T., Yamashita T., Umeda F., et al. High incidence of silent myocardial ischemia in elderly patients with non insulin dependent diabetes mellitus. Diabetes Res Clin Pract 47 (2000) 37-44
25. Gazzaruso C., Garzaniti A., Giordanetti S., et al. Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care 25 (2002) 1418-1424
26. Vinik A.I., Maser R.E., Mitchell B.D., and Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26 (2003) 1553-1579
27. Airaksinen K.E. Silent coronary artery disease in diabetes: a feature of autonomic neuropathy or accelerated atherosclerosis?. Diabetologia 44 (2001) 259-266
28. Ewing D.J., Martyn C.N., Young R.J., and Clarke B.F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8 (1985) 491-498
29. Zoneraich S., Silverman G., and Zoneraich O. Primary myocardial disease, diabetes mellitus, and small vessel disease. Am Heart J 100 5 (Nov 1980) 754-755
30. Stanley W.C., Lopaschuk G.D., and McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34 1 (Apr 1997) 25-33
31. Kantor P.F., Lucien A., Kozak R., and Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 5 (Mar 17 2000) 580-588
32. Dalla Volta S., Maraglino G., Della Valentina P., et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind crossover study. Cardiovasc Drugs Ther 4 (1990) 853-859
33. Detry J.M., Sellier P., PennaLorte S., et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37 (1994) 279-288
34. Michaelides A.P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 13 (1997) 8-14
35. Szwed H., Pachocki R., Domnzal-Bochenska M., et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drugs Ther 13 (1999) 215-220
36. Rebrova T., Afanas'eva S.A., Perchatkin V.A., Maksimov I.V., and Markov V.A. The protective effect of trimetazidine on the myocardium against reperfusion injury during thrombolytic therapy of acute infarction. Eksp Klin Farmakol 67 2 (Mar-Apr 2004) 27-30
37. Barsotti A., and Di Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 5 Suppl 2 (Mar 2004) 29S-36S
38. Ikizler M., Dernek S., Sevin B., and Kural T. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia. Anadolu Kardiyol Derg 3 4 (Dec 2003) 303-308
39. Belardinelli R. Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine. Ital Heart J 5 Suppl 2 (Mar 2004) 23S-28S [Italian]
40. Rosano G.M., Vitale C., Sposato B., Mercuro G., and Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2 1 (Nov 28 2003) 16
41. Fragasso G., Piatti Md.P.M., Monti L., et al. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146 5 (Nov 2003) E18
42. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 20 (Oct 2004) 1814-1821
43. El-Kadi T., El-Sabban K., Gabaly M., Sabry A., and Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drug 5 4 (2005) 271-278